Establishment Labs price to sales ratio ESTA

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 7.7×
8-year median: 8.4×
Against its 8-year history: 39th; percentile: 0 is its lowest day, 100 its highest
8-year range: 3.0× to 22.5×
Peer median: 3.4×

Establishment Labs' price to sales ratio is 7.7× as of Oct 23, 2026.

That is below its 8-year median of 8.4×, close to the middle of its last 8 years.

Over that time it ranged from 3.0× in Mar 2020 to 22.5× in Jul 2021.

The median for 10 medical instruments and supplies stocks of a similar size is 3.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.7×	7.2×	12.0×
2025	11.6×	5.2×	11.6×
2024	8.4×	3.9×	10.0×
2023	3.8×	3.2×	11.3×
2022	10.4×	8.8×	15.6×
2021	13.7×	10.8×	22.5×
2020	10.8×	3.0×	10.8×
2019	6.8×	4.9×	8.9×

Against its peers

Companies in Medical - Instruments & Supplies nearest Establishment Labs' size, closest first, today.

Company	Price to sales ratio
ESTAEstablishment Labs	7.7×
LMATLemaitre Vascular	7.4×
INSPInspire Medical Systems	2.3×
UFPTUFP Technologies	3.6×
EYENational Vision	0.7×
CDRECadre	1.9×
BVSBioventus	2.2×
ATRCAtriCure	5.3×
STAAStaar Surgical	3.3×
WRBYWarby Parker	3.5×
IRMDIradimed	12.7×
Peer median	3.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Establishment Labs

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.